Along with cancer progression, following the “equilibrium” and “escape” phases of cancer immune-editing, tumor microenvironment elicits the alternative, M2, activation of TAMs, induced by the secretion of cytokines, such as IL-4 and IL-13, by Th2 cells, basophils, and eosinophils [144]. The gene discussed is IL13; the disease is cancer.